|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun S, Schiller JH, Spinola M and Minna
JD: New molecularly targeted therapies for lung cancer. J Clin
Invest. 117:2740–2750. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rolfo C, Sortino G, Smits E, Passiglia F,
Bronte G, Castiglia M, Russo A, Santos ES, Janssens A, Pauwels P
and Raez L: Immunotherapy: Is a minor god yet in the pantheon of
treatments for lung cancer? Expert Rev Anticancer Ther.
14:1173–1187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fazilleau N, Mark L, McHeyzer-Willams LJ
and McHeyzer-Williams MG: Follicular helper T cells: Lineage and
location. Immunity. 30:324–335. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Inoue S, Leitner WW, Golding B and Scott
D: Inhibitory effects of B cells on antitumor immunity. Cancer Res.
66:7741–7747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee-Chang C, Bodogai M, Martin-Montalvo A,
Wejksza K, Sanghvi M, Moaddel R, de Cabo R and Biragyn A:
Inhibition of breast cancer metastasis by resveratrol-mediated
inactivation of tumor-evoked regulatory B cells. J Immunol.
191:4141–4151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O'Callaghan G and Houston A: Prostaglandin
E2 and the EP receptors in malignancy: Possible therapeutic
targets? Br J Pharmacol. 172:5239–5250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pai R, Soreghan B, Szabo IL, Pavelka M,
Baatar D and Tarnawski AS: Prostaglandin E2 transactivates EGF
receptor: A novel mechanism for promoting colon cancer growth and
gastrointestinal hypertrophy. Nat Med. 8:289–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baratelli F, Lin Y, Zhu L, Yang SC,
Heuzé-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S and
Dubinett SM: Prostaglandin E2 induces FOXP3 gene expression and T
regulatory cell function in human CD4+ T cells. J Immunol.
175:1483–1490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chemnitz JM, Parry RV, Nichols KE, June CH
and Riley JL: SHP-1 and SHP-2 associate with immunoreceptor
tyrosine-based switch motif of programmed death 1 upon primary
human T cell stimulation, but only receptor ligation prevents T
cell activation. J Immunol. 173:945–954. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park JJ, Omiya R, Matsumura Y, Sakoda Y,
Kuramasu A, Augustine MM, Yao S, Tsushima F, Narazaki H, Anand S,
et al: B7-H1/CD80 interaction is required for the induction and
maintenance of peripheral T-cell tolerance. Blood. 116:1291–1298.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen JH, Perry CJ, Tsui YC, Staron MM,
Parish IA, Dominguez CX, Rosenberg DW and Kaech SM: Prostaglandin
E2 and programmed cell death 1 signaling coordinately impair CTL
function and survival during chronic viral infection. Nat Med.
21:327–334. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rami-Porta R, Bolejack V, Giroux DJ,
Chansky K, Crowley J, Asamura H and Goldstraw P; International
Association for the Study of Lung Cancer Staging and Prognostic
Factors Committee, Advisory Board Members and Participating
Institutions, : The IASLC lung cancer staging project: The new
database to inform the eighth edition of the TNM classification of
lung cancer. J Thorac Oncol. 9:1618–1624. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garnelo M, Tan A, Her Z, Yeong J, Lim CJ,
Chen J, Lim KH, Weber A, Chow P, Chung A, et al: Interaction
between tumour-infiltrating B cells and T cells controls the
progression of hepatocellular carcinoma. Gut. 66:342–351. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pagès F, Galon J, Dieu-Nosjean MC, Tartour
E, Sautès-Fridman C and Fridman WH: Immune infiltration in human
tumors: A prognostic factor that should not be ignored. Oncogene.
29:1093–1102. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin Z, Chen X, Li Z, Luo Y, Fang Z, Xu B
and Han M: PD-1 antibody monotherapy for malignant melanoma: A
systematic review and meta-analysis. PLoS One. 11:e01604852016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Bao Z, Zhang X, Li F, Lai T, Cao
C, Chen Z, Li W, Shen H and Ying S: Effectiveness and safety of
PD-1/PD-L1 inhibitors in the treatment of solid tumors: A
systematic review and meta-analysis. Oncotarget. 8:59901–59914.
2017.PubMed/NCBI
|
|
20
|
Yang L, Yamagata N, Yadav R, Brandon S,
Courtney RL, Morrow JD, Shyr Y, Boothby M, Joyce S, Carbone DP and
Breyer RM: Cancer-associated immunodeficiency and dendritic cell
abnormalities mediated by the prostaglandin EP2 receptor. J Clin
Invest. 111:727–735. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nataraj C, Thomas DW, Tilley SL, Nguyen
MT, Mannon R, Koller BH and Coffman TM: Receptors for prostaglandin
E(2) that regulate cellular immune responses in the mouse. J Clin
Invest. 108:1229–1235. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
von der Emde L, Goltz D, Latz S, Müller
SC, Kristiansen G, Ellinger J and Syring I: Prostaglandin receptors
EP1-4 as a potential marker for clinical outcome in urothelial
bladder cancer. Am J Cancer Res. 4:952–962. 2014.PubMed/NCBI
|
|
23
|
Han L, Liu F, Li R, Li Z, Chen X, Zhou Z,
Zhang X, Hu T, Zhang Y, Young K, et al: Role of programmed death
ligands in effective T-cell interactions in extranodal natural
killer/T-cell lymphoma. Oncol Lett. 8:1461–1469. 2014.PubMed/NCBI
|
|
24
|
Zitvogel L and Kroemer G: Targeting
PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology.
1:1223–1225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sakaguchi S, Vignali DA, Rudensky AY, Niec
RE and Waldmann H: The plasticity and stability of regulatory T
cells. Nat Rev Immunol. 13:461–467. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yun X, Shang Y and Li M: Effect of
Lactobacillus salivarius on Th1/Th2 cytokines and the number of
spleen CD4+ CD25+ Foxp3+ Treg in asthma Balb/c mouse. Int J Clin
Exp Pathol. 8:7661–7674. 2015.PubMed/NCBI
|
|
27
|
Che D, Zhang S, Jing Z, Shang L, Jin S,
Liu F, Shen J, Li Y, Hu J, Meng Q, et al: Macrophages induce EMT to
promote invasion of lung cancer cells through the IL-6-mediated
COX-2/PGE2/β-catenin signalling pathway. Mol Immunol. 90:197–210.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fan Y, Wang Y and Wang K: Prostaglandin E2
stimulates normal bronchial epithelial cell growth through
induction of c-Jun and PDK1, a kinase implicated in oncogenesis.
Respir Res. 16:1492015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Quan Y, Jiang J and Dingledine R: EP2
receptor signaling pathways regulate classical activation of
microglia. J Biol Chem. 288:9293–9302. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cho JS, Han IH, Lee HR and Lee HM:
Prostaglandin E2 Induces IL-6 and IL-8 Production by the EP
Receptors/Akt/NF-κB pathways in nasal polyp-derived fibroblasts.
Allergy Asthma Immunol Res. 6:449–457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim JI, Lakshmikanthan V, Frilot N and
Daaka Y: Prostaglandin E2 promotes lung cancer cell migration via
EP4-betaArrestin1-c-Src signalsome. Mol Cancer Res. 8:569–577.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Israel DD and Regan JW: EP(3) prostanoid
receptor isoforms utilize distinct mechanisms to regulate ERK 1/2
activation. Biochim Biophys Acta. 1791:238–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Amano H, Hayashi I, Endo H, Kitasato H,
Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto
Y, et al: Host prostaglandin E(2)-EP3 signaling regulates
tumor-associated angiogenesis and tumor growth. J Exp Med.
197:221–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
